

1 **Title: Estimating the seroincidence of scrub typhus using antibody dynamics following**
2 **infection**

3
4
5 **Authors:** Kristen Aiemjoy^{1,2}, Nishan Katuwal³, Krista Vaidya¹, Sony Shrestha³, Melina Thapa³,
6 Peter Teunis⁴, Isaac I. Bogoch⁵, Paul Trowbridge⁶, Pacharee Kantipong⁷, Stuart D. Blacksell^{8,9}, Tri
7 Wangrangsimakul⁸, George M Varghese¹⁰, Richard Maude^{8,9,11,12}, Dipesh Tamrakar³, Jason R.
8 Andrews¹³

9
10
11 **Affiliations:**

- 12 1. Department of Public Health Sciences, University of California Davis School of Medicine, Davis,
13 CA, USA
14 2. Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University,
15 Bangkok Thailand
16 3. Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Nepal
17 4. Center for Global Safe Water, Sanitation and Hygiene, Hubert Department of Global Health,
18 Rollins School of Public Health, Emory University, Atlanta, GA, USA
19 5. Department of Medicine, University of Toronto, Toronto, ON, Canada
20 6. Michigan State University School of Human Medicine, Grand Rapids, MI, USA
21 7. Department of Internal Medicine, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
22 8. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol
23 University, Bangkok Thailand
24 9. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
25 Oxford, Oxford, UK
26 10. Department of Infectious Diseases, Christian Medical College, Vellore, India
27 11. The Open University, Milton Keynes, UK
28 12. School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
29 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
30 13. Division of Infectious Diseases and Geographic Medicine, Stanford University School of
31 Medicine, Stanford, CA, USA

32
33
34 **Corresponding Author:**

35 Kristen Aiemjoy
36 Assistant Professor
37 Division of Epidemiology
38 Department of Public Health Sciences,
39 University of California Davis School of Medicine, Davis, CA, USA
40 Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University,
41 Bangkok Thailand
42 kaiemjoy@ucdavis.edu

43
44
45
46 **Word Count: 3721**

49 **Abstract**

50

51 Introduction: Scrub typhus is an acute febrile illness caused by the bacterium *Orientia*
52 *tsutsugamushi*. Characterizing the population-level burden of scrub typhus is challenging due to
53 the lack of accessible and accurate diagnostics. In this study, we present a novel approach that
54 utilizes information on antibody dynamics after infection to generate population-level scrub typhus
55 seroincidence estimates from cross-sectional serosurveys.

56

57 Methods: We use data from three cohorts of scrub typhus patients enrolled in Chiang Rai,
58 Thailand, and Vellore, India, and representative population data from two serosurveys in and
59 around the Kathmandu valley, Nepal, and Vellore, India. The samples were tested for IgM and IgG
60 responses to *Orientia tsutsugamushi*-derived recombinant 56-kDa antigen using commercial
61 ELISA kits. We used Bayesian hierarchical models to fit two-phase models to the antibody
62 responses from scrub typhus cases and used the joint distributions of the peak antibody titers and
63 decay rates to estimate population-level incidence rates in the cross-sectional serosurveys. We
64 compared this new method to a traditional cut-off-based approach for estimating seroincidence.

65

66 Results: Median IgG antibodies persisted above OD 1.7 for 22 months, while IgM displayed longer
67 persistence than expected, with 50% of participants having an OD >1 for 5 months. We estimated
68 an overall seroincidence of 18 per 1000 person-years (95% CI: 16-21) in India and 4 per 1000
69 person-years (95% CI: 3-6) in Nepal. Among 18 to 29-year-olds, the seroincidence was 8 per 1000
70 person-years (95% CI 4 -16) in India and 9 per 1000 person-years (95% CI: 6-14) in Nepal. In both
71 India and Nepal, seroincidence was higher in urban and periurban settings compared to rural
72 areas. Compared to our method, seroincidence estimates derived from age-dependent IgG-
73 seroprevalence without accounting for antibody decay underestimated the disease burden by 50%.
74 By incorporating antibody dynamics, the approach described here provides more accurate age-
75 specific infection risk estimates, emphasizing the importance of considering both IgG and IgM
76 decay patterns in scrub typhus seroepidemiology.

77

78 Conclusion: The sero-surveillance approach developed in this study efficiently generates
79 population-level scrub typhus seroincidence estimates from cross-sectional serosurveys. This
80 methodology offers a valuable new tool for informing targeted prevention and control strategies,
81 ultimately contributing to a more effective response to scrub typhus in endemic regions worldwide.

82

83 Keywords: *Orientia tsutsugamushi*, *Scrub Typhus*, *Antibody kinetics*, *Seroepidemiology*, *incidence*

84

85

86

87

88

89 Introduction

90 Scrub typhus, an acute febrile illness caused by the bacterium *Orientia tsutsugamushi* (OT), is an
91 important, under-recognized etiology of fever (1). Once thought to be restricted to the
92 “tsutsugamushi triangle”, a region spanning from Russia to Pakistan, Australia, and Japan, recent
93 studies have identified scrub typhus transmission in South America, Africa, and the Middle East
94 (2–4). Infections occur when trombiculid mite chiggers (larvae) enter a host’s skin through hair
95 follicles and feed on lysed skin tissue. The mites, both vectors and reservoirs of OT, feed on
96 various mammals, including humans and rodents (5). In humans, symptoms are non-specific and
97 include fever, myalgia, headache, gastrointestinal symptoms, and rash. An eschar is found at the
98 inoculation site in a variable proportion of cases and is frequently missed on clinical examination.
99 Case fatality rates are estimated to be 1-2% among treated patients and 6% among untreated
100 patients (6).

101
102 Determining where scrub typhus transmission occurs is critical to inform public health interventions
103 and research priorities. Clinical incidence underestimates the true underlying burden of disease
104 due to non-specific symptoms and the lack of accessible and accurate diagnostics (7). Periodic
105 serosurveillance studies across endemic countries have demonstrated significant heterogeneity in
106 seroprevalence within and between countries (8). However, directly comparing seroprevalence is
107 not straightforward because of differences in the age distributions of each sampled population and
108 uncertainty in antibody-waning patterns.

109
110 Here, we apply a novel analytic approach to estimate scrub typhus seroincidence using antibody
111 decay information from confirmed cases. The decay of antibody concentrations defines a timescale
112 for inferring when an infection occurred. This approach does not depend on classification using
113 cutoffs, which have been difficult to derive for scrub typhus across locations with varying forces of

114 infection (9). We first model longitudinal IgG and IgM antibody responses to OT-derived antigens
115 among confirmed scrub typhus cases in Thailand and India and then use these parameters to
116 estimate scrub typhus seroincidence from cross-sectional population serosurveys in Nepal and
117 India.

118

119

120 **Methods**

121 Study populations and enrollment

122 *Scrub typhus cases:* We used antibody responses measured from confirmed scrub typhus patients
123 enrolled in three studies: two in Thailand and one in India. The first study in Thailand enrolled
124 children less than 18 years old who were admitted to Chiang Rai Prachanukroh Hospital with fever
125 (temperature higher than 37.5°C) or a history of fever within the last 14 days(10). Enrollment
126 occurred between July 2015 to August 2016. Confirmed scrub typhus infections were defined by
127 meeting at least one of the following criteria: (1) a positive PCR or culture result from either a blood
128 or eschar sample, (2) a fourfold rise in the IgM titer to $\geq 1:3200$ in paired serum or plasma samples,
129 or (3) a single IgM titer of $\geq 1:3200$ in an acute-phase serum or plasma sample(11,12). Blood
130 samples were collected at baseline and at 2-, 12-, and 52-weeks after enrollment, stored at -80°C ,
131 and transported to Bangkok for diagnostic processing.

132

133 The second study In Thailand enrolled hospitalized patients older than 15 years from a fever
134 surveillance study also at the Chiang Rai Prachanukhao Hospital (13,14). Enrollment occurred
135 from August 2007 to August 2008. Patients confirmed to be infected with scrub typhus were
136 defined by meeting at least one of the following criteria: (1) *In vitro* isolation of *O. tsutsugamushi*,
137 (2) a ≥ 4 -fold rise in IgM titer in paired serum samples when tested by the indirect
138 immunofluorescence assay, (3) a positive result in at least two out of the three PCR assays

139 described in Paris et al., 2011(14). Serum samples were collected at admission and stored at
140 -80°C until testing.

141

142 In India, serum samples were collected from individuals infected with scrub typhus who were > 18
143 years old and sought care at Christian Medical College Teaching Hospital in Vellore, India,
144 between December 2011 and March 2015 (15). Confirmed patients with scrub typhus were defined
145 by a positive IgM ELISA (optical density (OD) >0.8) and/or a positive PCR for *O. tsutsugamushi*.
146 The serum samples were collected cross-sectionally from retrospective cases with diagnoses
147 between 2 months and 3.5 years prior. Serum samples were collected in the patient's household,
148 stored at -80°C , and processed within two weeks of collection.

149

150 *Population samples:* In Nepal, we enrolled a geographically random, population-based cross-
151 sectional sample of individuals aged 0 to 25 years from the catchment areas of Kathmandu
152 University Teaching Hospital in Kathmandu (urban), and Dhulikhel Hospital in Kavrepalanchok,
153 Nepal (periurban and rural) (16). Within catchment areas, we randomly selected geographically
154 defined grid clusters and enumerated all households in each cluster. From this census, we
155 randomly selected individuals and sought consent. We collected capillary blood samples from
156 consenting participants onto TropBio™ filter papers (Cellabs Pty Ltd., Brookvale, New South
157 Wales, Australia). The samples were air-dried for at least two hours at room temperature, then
158 stored with desiccant in individual plastic bags at -20°C until processing. Study participants were
159 enrolled between February 2019 and Jan 2021. In India, we utilized a previously-conducted cross-
160 sectional serosurvey for scrub typhus conducted from September 2014 to December 2014(17).
161 The study enrolled adults ≥ 18 years of age in the Vellore District of Tamil Nadu in South India. A
162 two-stage clustered sample design was used to randomly select communities and individuals(17).

163 Venous blood was collected from consenting participants, transported on ice, and stored at -70°C
164 until tested.

165

166 Laboratory methods

167 All samples were tested using IgM and IgG responses to *O. tsutsugamushi*-derived recombinant
168 56-kDa antigen using the Scrub Typhus Detect ELISA kit (InBios International, Inc., Seattle, WA,
169 USA)(13) performed as per the manufacturer's instructions. All serum samples were tested at a
170 1:100 dilution, and the results were read at 450 nm using a microplate reader (Thermo Scientific
171 Multiskan FC) to generate a final optical density result (optical density (OD) at 450 nm). To prepare
172 the dried capillary blood samples used in Nepal, we cut two filter paper protrusions and submerged
173 them in 133 μ L of 1XPBS 0.05% Tween buffer overnight at 4 C, then centrifuged to recover the
174 eluates. The eluate was assumed to be equivalent to a 1:10 dilution of plasma.

175

176 Statistical methods

177 We estimated seroincidence in two ways: 1) by deriving it from the age-dependent seroprevalence
178 and 2) as a function of the longitudinal antibody dynamics after infection. For method 1, we used
179 finite mixture models to determine the IgG seropositivity cutoffs using the mean plus two standard
180 deviations of the first mixture component (18). We calculated IgG seroprevalence as the proportion
181 of individuals classified as IgG seropositive. We then used an exponential survival model to derive
182 seroincidence (equations 1 & 2), where $\pi(a)$ equals the seroprevalence at age (a) and λ equals
183 the seroincidence rate.

184

185

186

187

188

$$eq\ 1. \quad \pi(a) = 1 - e^{-\lambda a}$$

$$eq\ 2. \quad \lambda = \frac{(-\log_{10}(1 - \pi(a)))}{a}$$

189 We fit a generalized linear model to the binomial seropositivity outcome conditional on age with a
190 complementary log-log link and estimated seroincidence from the model's intercept term (19,20).
191 This approach assumes there is no antibody waning over time and that seroincidence is constant
192 over age. To evaluate how seropositivity changes over age, we fit generalized additive models (21)
193 with a cubic spline for age and simultaneous confidence intervals using a parametric bootstrap of
194 the variance-covariance matrix of the fitted model parameters (22).

195

196 For method 2, we used information about antibody decay from confirmed cases to estimate
197 seroincidence. First, we modeled longitudinal antibody dynamics after scrub typhus infection using
198 two-phase models with an infection episode characterized by an exponential rise in antibody
199 response and a non-exponential power function decay (23–25). We model antibody kinetics from
200 onset of fever ($t = 0$) with initial antibody levels of y_0 reaching a peak antibody response of y_1 . We
201 used a Bayesian hierarchical framework to fit the above models for IgG and IgM (23,24) and
202 generate joint distributions using Markov chain Monte Carlo (MCMC) sampling, allowing for
203 individual variation. We implemented the models in R version 4.1.3 using JAGS(26).

204

205 We used the distributions of peak antibody response and the decay rate and shape to estimate
206 seroincidence in the cross-sectional population samples(27). We created a likelihood function for the
207 observed cross-sectional population data based on the longitudinal kinetics following scrub typhus
208 infection with the assumption that incident infections occur as a Poisson process with rate lambda
209 (λ (28). We generated maximum likelihood profiles for λ using each isotype separately and jointly by
210 combining their likelihood functions. We accounted for two sources of noise in the observed serologic
211 responses: measurement noise of the assay and biologic noise as detailed in Teunis et. al. (27).

212

213 Ethics statement

214 Institutional Review Boards in India (Christian Medical College, Vellore), Thailand (Chiang Rai
215 Hospital, the Faculty of Tropical Medicine, Mahidol University, and the Thai Ministry of Public
216 Health), The United States (Stanford University Institutional Review Board), and Nepal (Nepal
217 Health Research Council Ethical Review Board)) approved the study forms and protocols.

218

219 **Results**

220 ELISA antibody responses were measured from 288 patients with confirmed scrub typhus
221 infections: 77 in Thailand and 211 in India (15). Samples were collected between 0 and 1300 days
222 after symptom onset. In the pediatric cohort in Thailand, 4 samples were collected between 0 400
223 days after symptom onset. In the adult cohorts in India and Thailand, just one sample was
224 collected between 1 and 11 days after symptom onset (median 5.5) in Thailand and between 65
225 and 1250 days after symptom onset (median 599) in India. The adult cohort in Thailand did not
226 measure IgG responses. The median ages of participants were 44 years (IQR 27-55, range 1.2 -
227 84); 47 in India (IQR 35-57), and 43 in the adult cohort in Thailand (IQR 35-51) and 6.6 (IQR 4 –
228 10) in the pediatric cohort in Thailand (Table 1).

229

230

231

232

233

234

235

236

237

238 **Table 1: Summary of longitudinal scrub typhus patient data**

	India: Adult (N=211)	Thailand: Pediatric (N=35)	Thailand: Adult (N=42)	Overall (N=288)
Age (years)				
Median (IQR)	47 (35 - 57)	6.6 (4.0 - 10)	43 (35 - 51)	44 (27 - 55)
Min/Max	19 - 79	1.2 - 13	15 - 84	1.2 - 84
Missing	0 (0%)	0 (0%)	1 (2.4%)	1 (0.3%)
Days from symptom onset to first visit				
Median (IQR)	520 (340 - 880)	10 (7.5 - 12)	5.5 (4.0 - 7.0)	380 (13 - 750)
Min/Max	65 - 1300	3.0 - 19	0.15 - 11	0.15 - 1300
Days from symptom onset to last visit				
Median (IQR)	-	350 (350 - 370)	-	350 (350 - 370)
Min/Max		10 - 400		10 - 400
Number of visits				
Median (IQR)	1.0 (1.0 - 1.0)	4.0 (4.0 - 4.0)	1.0 (1.0 - 1.0)	1.0 (1.0 - 1.0)
Min/Max	1.0 - 1.0	1.0 - 4.0	1.0 - 1.0	1.0 - 4.0

239
240
241 Median IgG responses were elevated above the mixture model cut-off for 22.3 months after
242 symptom onset (Figure 2A). An OD of 1 has been suggested as a reasonable cutoff to indicate a
243 recent infection (29,30). In our study population, median responses were elevated about an OD of
244 1 for 5.3 months after infection, 25% of the population had elevated for 12.5 months and 10% had
245 elevated responses for 26.5 months. IgM responses decayed at a rate of OD 1.7 (95% credible
246 interval (CrI) 0.77 – 3.77) per month compared to 0.11 (95% CrI 0.04 – 0.29) per month for IgG).
247 IgM responses peaked at OD 5.12 (95% CrI 4.00 – 7.03), 5.2 days (95% CrI 3.4 – 7.6) after
248 symptom onset. IgG responses peaked at OD 2.8 (95% CrI 2.1 – 3.73) 11 days (95% CrI 5.7 –
249 20.6) after symptom onset. (Supplemental Table 2).

250
251 For the population data, ELISA antibody responses were measured from 721 participants in
252 Vellore, India, and 1105 participants in Kathmandu and Kavre districts, Nepal. The median age of

253 participants was 49 in India (IQR 40-62) and 11 in Nepal (IQR 5.5-17). In India, 63.2% (456/721) of
 254 participants were female, compared to 48.7% (538/1105) in Nepal (Table 2).

255 **Table 2: Population data summary**

	India (N=721)	Nepal (N=1105)
Age, in years		
Median (IQR)	49 (40 - 62)	11 (5.5 - 17)
Min/Max	18 - 87	0.90 - 27
Age, in years, Categorical		
0-17	0 (0%)	876 (79.3%)
18-29	59 (8.2%)	229 (20.7%)
30-49	302 (41.9%)	0 (0%)
50-89	360 (49.9%)	0 (0%)
Gender		
Female	456 (63.2%)	538 (48.7%)
Male	265 (36.8%)	567 (51.3%)
Residence zone		
Rural	177 (24.5%)	316 (28.6%)
Periurban	284 (39.4%)	319 (28.9%)
Urban	190 (26.4%)	470 (42.5%)
Missing	70 (9.7%)	0 (0%)
Occupation		
Agriculture	85 (11.8%)	0 (0%)
Labor & Manufacturing	181 (25.1%)	14 (1.3%)
Minor, <=18 years	1 (0.1%)	880 (79.6%)
None	343 (47.6%)	152 (13.8%)
Other	21 (2.9%)	21 (1.9%)
Professional	44 (6.1%)	26 (2.4%)
Service	46 (6.4%)	12 (1.1%)
Household size		
Median (IQR)	4.0 (3.0 - 5.0)	4.0 (4.0 - 6.0)
Missing	3 (0.4%)	1 (0.1%)

256

257 In both India and Nepal, the seroprevalence of scrub typhus infection increased with age (Figure
 258 3). In Vellore, India the overall seroprevalence was 29.8% (95% CI 26.5-33.2): growing from 10.2%
 259 (95% CI 2.4-17.9) among 18-29-year-olds to 38.1% (95% CI 33.0-43.1) among 50 to 89-year-olds.
 260 In Kathmandu and Kavre, Nepal, the overall seroprevalence was 1.2% (95% CI 0.5-1.8), rising
 261 from 0.1% (95%CI 0-0.3) among 0 to 17-year-olds to 5.2% (95%CI 2.3 – 8.1%) among 18-29-year-
 262 olds (Table 3).

263

264 **Table 3: Age-specific seroprevalence and seroincidence in Nepal and India**

265

Age	N	N IgG seropositive	IgG seroprevalence (95% CI)	Seroincidence per 1000 person-years (95% CIs)		
				IgG antibody kinetics	IgG and IgM antibody kinetics	Derivative of age-dependent IgG seroprevalence
India						
0-17	0	0	–	–	–	–
18-29	59	6	10.2% (2.4-17.9)	8 (4-16)	11 (6-18)	4 (2-10)
30-49	302	72	23.8% (19.0-28.7)	14 (11-18)	12 (10-15)	7 (5-9)
50-89	360	137	38.1% (33.0-43.1)	26 (21-32)	20 (17-24)	8 (6-9)
Overall	721	215	29.8% (26.5-33.2)	18 (16-21)	16 (14-18)	7 (6-8)
Nepal						
0-17	876	1	0.1% (0-0.3)	2 (1-4)	–	0 (0-1)
18-29	229	12	5.2% (2.3-8.1)	9 (6-14)	–	3 (1-4)
30-49	0	0	–	–	–	–
50-89	0	0	–	–	–	–
Overall	1105	13	1.2% (0.5-1.8)	4 (3-6)	–	1 (1-2)

266

267 In Vellore, India, the overall scrub typhus seroincidence rate was 18 per 1000 person-years (95%

268 CI: 16 - 21) using IgG antibody dynamics. Seroincidence rose with age; growing from 8 (95% CI 4 -

269 16) among 18-29 year-olds to 26 (95% CI 21 - 32) among 50-89-year-olds. In the Kathmandu
270 valley of Nepal, the overall seroincidence was 4 (95% CI 3 – 6) per 1000 person-years, also rising
271 with age from 2 (95% CI 1 - 4) per 1000 person-years among 0 to 17-year-olds to 9 (95%CI 6 -14)
272 among 18 to 29-year-olds. In both Nepal and India, the overall seroincidence using antibody
273 dynamics was more than double the seroincidence derived from the age-dependent IgG-
274 seroprevalence, 2.6 times higher in India and 4 times higher in Nepal (Table 3). IgM responses
275 were only available from the study in India; there, the seroincidence using IgM was similar to IgG.
276 The confidence intervals using IgM and IgG together were more narrow than using IgG alone.

277

278 In both sites, scrub typhus seroincidence varied by resident zones. In Vellore, India, seroincidence
279 was highest in periurban settings across all age groups, followed by rural and then urban, whereas
280 in Nepal, seroincidence was higher in urban settings (Figure 4). In India, females had slightly
281 elevated seroincidence rates compared to males across all age groups, although the confidence
282 intervals overlapped (Figure 4).

283

284 **Discussion**

285 In this study, we developed and applied a novel analytic approach to estimate the seroincidence of
286 scrub typhus using antibody decay information from confirmed cases in Thailand and India and
287 cross-sectional population serosurveys in Nepal and India. Seroincidence, the number of new
288 infections in a population per year, characterizes transmission intensity and is highly informative for
289 determining where and among whom infection burden is highest. We found a high seroincidence
290 of scrub typhus in both study populations, underscoring the importance of addressing the burden of
291 scrub typhus infection in these regions. A key finding of our study involves delineating the
292 persistence of antibodies after infection, characterizing their decay rate and shape, and using this
293 information to interpret population-level responses. Our results demonstrate that employing the

294 cutoff method to estimate seroprevalence while disregarding antibody decay underestimates the
295 true burden of scrub typhus infection.

296

297 Most cross-sectional seroepidemiologic studies on scrub typhus rely on seroprevalence as a
298 marker of infection, employing a cutoff threshold to dichotomize IgG responses and calculating the
299 proportion of the population with values above the threshold (6,8,31). Antibody responses in a
300 population at any given time will be a function of exposure, the age of the population, and antibody
301 persistence. For example, in our study populations, the overall seroprevalence was much higher in
302 India than in Nepal; however, in India, the median age of patients was 49 years compared to the
303 median age of 11 years in Nepal. Despite differences in overall seroprevalence rates, the
304 discrepancies in age-specific seroprevalence rates between the two populations were less marked.
305 This underlines the importance of considering age-specific seroprevalence rates when comparing
306 seroprevalence between different populations, as the age distribution can have a considerable
307 impact on the observed seroprevalence. Our novel analytical approach, which accounts for age
308 and antibody decay, provides a more accurate representation of scrub typhus infection in these
309 regions, highlighting the need for targeted public health interventions and research.

310

311 In both India and Nepal, seroprevalence increased notably with age, a finding that has been
312 consistently observed in other scrub typhus serosurveys (17,32). An increase in seroprevalence
313 with age can result from gradual accumulating in IgG responses over time or from a genuinely
314 elevated risk of infection in older age groups. Both arguments have been put forth for scrub typhus
315 seroepidemiology, with the suggestion that elevated risk in older ages is attributable to changes in
316 skin health, immune system function, and physiological processes (29). We argue that reporting
317 seroincidence rather than seroprevalence is essential to disentangling the effects of IgG
318 accumulation over age versus age-specific risk. Seroincidence, which measures the number of

319 new infections in a population per year, characterizes transmission intensity and is highly
320 informative for determining where and at what ages the infection burden is highest. Incorporating
321 antibody dynamics into the calculation of seroincidence, as demonstrated in this paper, further
322 elucidates age-specific changes in infection risk by accounting for decaying antibody levels. In our
323 study populations, we observed a marked increase in seroprevalence with age, while the increase
324 in seroincidence at older ages was comparatively more gradual. For example, in India, individuals
325 aged 50-89 had 3.8 times higher IgG seroprevalence compared to 18-29 year-olds compared to
326 1.8 times higher seroincidence using IgG and IgM antibody dynamics. This highlights the
327 importance of using seroincidence to better understand the age-specific risk of infection and to
328 inform targeted public health interventions.

329
330 Defining antibody dynamics and persistence is crucial for interpreting population-level
331 seroresponses to *Orientia tsutsugamushi* and modeling seroincidence. In our study, we found that
332 median IgG responses remained elevated above a mixture-model cutoff of 1.7 OD for nearly two
333 years. These findings align with a recent study by Schmidt et al., which reported that half of the
334 cases had persistent IgG antibodies beyond two years (29). Interestingly, IgM responses persisted
335 longer than anticipated. We observed that half of the participants had an OD <1 after 5.3 months
336 after symptom onset, and 90% of participants had an OD <1 for 26.5 months. This extended
337 persistence contrasts with Schmidt et al's findings, where half of the participants had IgM OD <1
338 after 2.7 months and 90% had OD <1 after 7.7 months. A potential explanation for this discrepancy
339 could be the difference in the duration of sample collection between the two studies. In the Schmidt
340 study, samples were collected up to a year after infection, while our study included samples
341 collected up to 3.5 years after infection. Another explanation could be the differences in modeling
342 approaches. Our power-function model allows for the shape of the decay to be non-exponential,
343 permitting a slower decay at longer times since infection. In contrast, a restricted cubic spline

344 approach may require a constant rate and shape of decay. It would be ideal to test these
345 approaches with the same data in future research. The persistence of IgM revealed in our study
346 suggests that it would be a good complement to IgG to identify recent infections and improve the
347 precision around seroincidence estimates. Indeed, for the India data where IgM results were
348 available, the seroincidence estimates using both IgM and IgG were consistent, yielding similar
349 estimates for the seroincidence, thus strengthening the validity of our approach. The seroincidence
350 estimates using IgM and IgG had narrower confidence intervals than those using IgG alone.

351

352 One of the key strengths of our approach lies in its ability to account for the inherent heterogeneity
353 of antibody responses, as well as measurement and biologic noise. Traditional seroepidemiological
354 methods, which rely on a single cutoff value for seroprevalence and seroincidence, fail to
355 incorporate these sources of variability. By explicitly integrating the heterogeneity in antibody
356 responses, our method captures the distribution of responses among individuals across ages,
357 clinical severity and levels of immune function. Additionally, our approach takes into account the
358 measurement noise associated with the ELISA assay and the biologic noise that stems from non-
359 specific antibody binding. This more comprehensive incorporation of uncertainty leads to more
360 accurate and robust estimates of scrub typhus seroincidence, which in turn better informs public
361 health interventions and research priorities.

362

363 Our findings have several implications for public health. First, we reveal a substantial subclinical burden
364 of scrub typhus beyond what is captured by the reporting of clinical cases. In India, a recent
365 population-based fever surveillance study conducted reported a clinical incidence of 0.8 cases per 1000
366 person-years, defined as the incidence of scrub typhus among febrile individuals who sought care or
367 were hospitalized (32). By applying our seroincidence estimates derived from IgG and IgM antibody
368 dynamics, we estimate that there are around 14 subclinical infections for every clinical case in the

369 population surrounding CMC Hospital. This inflation factor is less than estimated by Devamani et al.,
370 who reported a seroincidence of 44 per 1000 person-years. This study was conducted in a population
371 that was purposefully selected for its elevated numbers of clinical scrub typhus cases, which could
372 explain the differences (30). Population-based clinical incidence estimates for scrub typhus are not
373 currently available for the study population in Nepal but would be valuable in distinguishing clinical
374 versus sub-clinical infections. While individual health implications of subclinical infections are currently
375 unclear, seroincidence studies like ours are useful for identifying areas with substantial scrub typhus
376 burden, thereby informing the allocation of resources for enhanced clinical diagnostic capacity and
377 targeted surveillance efforts. Furthermore, our study challenges the notion that scrub typhus is solely a
378 rural disease. We observed elevated incidence rates in both urban and peri-urban communities in
379 Nepal and India. However, we could not ascertain whether exposure occurred at the place of residence
380 or was linked to rural exposure, highlighting the need for further research targeting these populations
381 and investigating exposures. Expanding our understanding of the distribution and risk factors
382 associated with scrub typhus in various settings will help inform the development of more effective and
383 targeted prevention and control measures, ultimately reducing the burden of disease in affected
384 populations.

385
386 There are several limitations to our study that warrant consideration. First, the population
387 serosurveys in India and Nepal were conducted over different time periods, with the Indian survey
388 spanning a few months and the Nepalese survey taking place over a year. This discrepancy could
389 introduce variability in the observed seroprevalence and seroincidence rates between the two
390 populations due to seasonal differences in scrub transmission. Second, our study assumes that the
391 antibody decay patterns observed in the cohorts from Thailand and India are applicable to the
392 populations in Nepal and India. This may not necessarily hold true, as factors such as age,
393 geography, clinical severity, and population-specific immune characteristics could lead to variations

394 in antibody decay patterns. Third, we estimated antibody dynamics using cases from a wide range
395 of ages. Although our sample size was not large enough to investigate age-specific variability in
396 kinetics, it is possible that these dynamics may vary with immune function at different ages,
397 presenting an interesting avenue for future research. Additionally, our findings may be influenced
398 by the overrepresentation of higher-risk groups in our data, such as women and urban residents,
399 which could affect the population-level seroincidence estimates. Future studies may benefit from
400 adjusting for potential biases introduced by overrepresented demographic groups. Lastly, we do
401 not have sufficient data to investigate whether antibody decay rates vary by age, which could
402 influence our seroincidence estimates. Despite these limitations, our study offers valuable insights
403 into the seroepidemiology of scrub typhus and highlights the importance of accounting for antibody
404 dynamics and heterogeneity in such analyses.

405

406 Scrub typhus remains an important but underrecognized etiology of acute fever with endemicity
407 expanding globally. There is a critical need for low-cost, accurate tools to quantify the burden of
408 scrub typhus infections to inform public health decision-making. We describe a sero-surveillance
409 approach that can efficiently generate population-level scrub typhus seroincidence estimates from
410 cross-sectional serosurveys. This methodology offers a valuable new tool for informing targeted
411 prevention and control strategies, ultimately contributing to a more effective response to scrub
412 typhus in endemic regions worldwide.

413

414

415

416

417

418

419

420

421

422

423

424 **Acknowledgments**

425

426 We gratefully acknowledge the study participants for their valuable time and interest in participating
427 in these studies.

428

429

430 **Funding**

431 This work was supported by the Fogarty International Center at National Institutes of Health [K01

432 TW012177-01A1]

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466 **Figures**

467

468 **Figure 1: Quantitative antibody responses among population serosurveys in Nepal and India.**

469 Anti-OT IgM and IgG responses are measured using kinetic enzyme-linked immunosorbent assays


470 (ELISAs) and depicted on the y-axis of all plots. The horizontal dashed line denotes the mixture model

471 cutoff. Panel A shows the distribution of responses among the population-based samples in India and

472 Nepal. Panel B shows the antibody among the population-based samples in India and Nepal as a

473 function of age.

474



475

476

477

478

479

480

481

482

483

484


485

486

487

488


489 **Figure 2: Kinetics of IgM responses among Scrub Typhus cases.** Longitudinal antibody
490 dynamics were modeled from ELISA-measured antibody responses using Bayesian hierarchical
491 models. The points are the observed individual antibody concentrations; each point indicates one
492 sample; a patient's samples are connected with light purple lines. The dark solid lines indicates the
493 median, and the 95% credible intervals for the model-fitted antibody decay concentrations. The
494 horizontal dashed line denotes the mixture model cutoff.
495
496



497
498
499
500
501
502
503
504
505
506
507
508
509
510
511

512 **Figure 3: Age-dependent seroprevalence**


513 Seroprevalence is depicted as a function of age. Seroprevalence was determined using the
514 mixture-model derived cutoff for IgG responses. The age-dependent seroprevalence was modeled
515 using a generalized additive model with a cubic spline for age and simultaneous confidence
516 intervals using a parametric bootstrap of the variance-covariance matrix of the fitted model
517 parameters.
518




519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539

540 **Figure 4: Seroincidence by age plus (A) resident zones and (B) gender**
541 Seroincidence rates across are shown across age strata, residence zone (A), and gender (B)
542 comparing the India and Nepal population samples. Seroincidence is estimated using IgG antibody
543 kinetics. The point represents the incidence estimate per 1000 person-years, and the bar indicates
544 the 95% confidence interval.

(A)



(B)




545
546

547
548
549
550
551

Supplemental material

Supplemental Figure 1: Sampling collection over time and geographic unit



552
553
554
555

Supplemental Table 1: Modeled antibody kinetic parameters

Median (95% Credible interval)

Parameter	IgG	IgM
Decay rate (1/years)??	0.11 (0.04-0.29)	1.70 (0.77-3.77)
Decay shape	1.34 (1.17-1.68)	2.05 (1.76-2.45)
Time to peak (days)??	11.04 (5.66-20.55)	5.19 (3.36-7.95)
Baseline response (OD)??	0.13 (0.07-0.24)	0.06 (0.04-0.10)
Peak response (OD)??	2.80 (2.10-3.73)	5.12 (4.00-7.03)

556
557
558
559

560

561 **References**

562

- 563 1. Paris DH, Shelite TR, Day NP, Walker DH. Unresolved Problems Related to Scrub Typhus: A
564 Seriously Neglected Life-Threatening Disease. *The American Journal of Tropical Medicine and*
565 *Hygiene*. 2013 Aug 7;89(2):301–7.
- 566 2. Weitzel T, Dittrich S, López J, Phuklia W, Martinez-Valdebenito C, Velásquez K, et al. Endemic
567 Scrub Typhus in South America. *N Engl J Med*. 2016 Sep 8;375(10):954–61.
- 568 3. Izzard L, Fuller A, Blacksell SD, Paris DH, Richards AL, Aukkanit N, et al. Isolation of a Novel
569 *Orientia* Species (*O. chuto* sp. nov.) from a Patient Infected in Dubai. *Journal of Clinical*
570 *Microbiology*. 2010 Dec;48(12):4404–9.
- 571 4. Thiga JW, Mutai BK, Eyako WK, Ng'ang'a Z, Jiang J, Richards AL, et al. High Seroprevalence
572 of Antibodies against Spotted Fever and Scrub Typhus Bacteria in Patients with Febrile Illness,
573 Kenya. *Emerg Infect Dis*. 2015 Apr;21(4):688–91.
- 574 5. Luce-Fedrow A, Lehman ML, Kelly DJ, Mullins K, Maina AN, Stewart RL, et al. A Review of
575 Scrub Typhus (*Orientia tsutsugamushi* and Related Organisms): Then, Now, and Tomorrow.
576 *Trop Med Infect Dis*. 2018 Jan 17;3(1):8.
- 577 6. Bonell A, Lubell Y, Newton PN, Crump JA, Paris DH. Estimating the burden of scrub typhus: A
578 systematic review. *PLOS Neglected Tropical Diseases*. 2017 Sep 25;11(9):e0005838.
- 579 7. John R, Varghese GM. Scrub typhus: a reemerging infection. *Current Opinion in Infectious*
580 *Diseases*. 2020 Oct;33(5):365–71.
- 581 8. Xu G, Walker DH, Jupiter D, Melby PC, Arcari CM. A review of the global epidemiology of
582 scrub typhus. *PLOS Neglected Tropical Diseases*. 2017 Nov 3;11(11):e0006062.
- 583 9. Saraswati K, Phanichkrivalkosil M, Day NPJ, Blacksell SD. The validity of diagnostic cut-offs for
584 commercial and in-house scrub typhus IgM and IgG ELISAs: A review of the evidence. *PLOS*
585 *Neglected Tropical Diseases*. 2019 Feb 4;13(2):e0007158.
- 586 10. Wangrangsimakul T, Greer RC, Chanta C, Nedsuwan S, Blacksell SD, Day NPJ, et al. Clinical
587 Characteristics and Outcome of Children Hospitalized With Scrub Typhus in an Area of
588 Endemicity. *Journal of the Pediatric Infectious Diseases Society*. 2020 Apr 30;9(2):202–9.
- 589 11. Lim C, Blacksell SD, Laongnualpanich A, Kantipong P, Day NPJ, Paris DH, et al. Optimal
590 Cutoff Titers for Indirect Immunofluorescence Assay for Diagnosis of Scrub Typhus. *Journal of*
591 *Clinical Microbiology*. 2015 Nov;53(11):3663–6.
- 592 12. Jiang J, Chan TC, Temenak JJ, Dasch GA, Ching WM, Richards AL. DEVELOPMENT OF A
593 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION ASSAY SPECIFIC FOR
594 *ORIENTIA TSUTSUGAMUSHI*. *The American Journal of Tropical Medicine and Hygiene*. 2004
595 Apr 1;70(4):351–6.
- 596 13. Blacksell SD, Tanganuchitcharnchai A, Nawtaisong P, Kantipong P, Laongnualpanich A, Day
597 NPJ, et al. Diagnostic Accuracy of the InBios Scrub Typhus Detect Enzyme-Linked

- 598 Immunoassay for the Detection of IgM Antibodies in Northern Thailand. *Clinical and Vaccine*
599 *Immunology* [Internet]. 2015 Dec 9 [cited 2022 Feb 20]; Available from:
600 <https://journals.asm.org/doi/abs/10.1128/CVI.00553-15>
- 601 14. Paris DH, Blacksell SD, Nawtaisong P, Jenjaroen K, Teeraratkul A, Chierakul W, et al.
602 Diagnostic Accuracy of a Loop-Mediated Isothermal PCR Assay for Detection of *Orientia*
603 *tsutsugamushi* during Acute Scrub Typhus Infection. *PLOS Neglected Tropical Diseases*. 2011
604 Sep 13;5(9):e1307.
- 605 15. Varghese GM, Rajagopal VM, Trowbridge P, Purushothaman D, Martin SJ. Kinetics of IgM and
606 IgG antibodies after scrub typhus infection and the clinical implications. *International Journal of*
607 *Infectious Diseases*. 2018 Jun 1;71:53–5.
- 608 16. Aiemjoy K, Seidman JC, Saha S, Munira SJ, Sajib MSI, Sium SMA, et al. Estimating typhoid
609 incidence from community-based serosurveys: a multicohort study. *The Lancet Microbe*
610 [Internet]. 2022 Jun 21 [cited 2022 Jun 23];0(0). Available from:
611 [https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(22\)00114-8/fulltext](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00114-8/fulltext)
- 612 17. Trowbridge P, P. D, Premkumar PS, Varghese GM. Prevalence and risk factors for scrub
613 typhus in South India. *Tropical Medicine & International Health*. 2017;22(5):576–82.
- 614 18. Bickel PJ, Klaassen CA, Bickel PJ, Ritov Y, Klaassen J, Wellner JA, et al. Efficient and
615 adaptive estimation for semiparametric models. Vol. 2. Springer New York; 1998.
- 616 19. Arnold BF, Martin DL, Juma J, Mkocha H, Ochieng JB, Cooley GM, et al. Enteropathogen
617 antibody dynamics and force of infection among children in low-resource settings. Ferguson
618 NM, Jit M, White M, Leung DT, Azman A, editors. *eLife*. 2019 Aug 19;8:e45594.
- 619 20. Jewell NP, van der Laan M. Generalizations of current status data with applications. *Lifetime*
620 *Data Anal*. 1995 Mar 1;1(1):101–9.
- 621 21. Wood SN. *Generalized additive models: an introduction with R*. Chapman and Hall/CRC; 2006.
- 622 22. Marra G, Wood SN. Coverage properties of confidence intervals for generalized additive model
623 components. *Scandinavian Journal of Statistics*. 2012;39(1):53–74.
- 624 23. de Graaf WF, Kretzschmar MEE, Teunis PFM, Diekmann O. A two-phase within-host model for
625 immune response and its application to serological profiles of pertussis. *Epidemics*. 2014
626 Dec;9:1–7.
- 627 24. Teunis PFM, van Eijkeren JCH, de Graaf WF, Marinović AB, Kretzschmar MEE. Linking the
628 seroresponse to infection to within-host heterogeneity in antibody production. *Epidemics*. 2016
629 Sep;16:33–9.
- 630 25. Teunis PFM, van der Heijden OG, de Melker HE, Schellekens JFP, Versteegh FGA,
631 Kretzschmar MEE. Kinetics of the IgG antibody response to pertussis toxin after infection with
632 *B. pertussis*. *Epidemiol Infect*. 2002 Dec;129(3):479–89.
- 633 26. Hornik K, Leisch F, Zeileis A. JAGS: A program for analysis of Bayesian graphical models
634 using Gibbs sampling. In: *Proceedings of DSC*. 2003.

- 635 27. Teunis PFM, van Eijkeren JCH. Estimation of seroconversion rates for infectious diseases:
636 Effects of age and noise. *Stat Med*. 2020 Sep 20;39(21):2799–814.
- 637 28. Teunis PFM, van Eijkeren JCH, Ang CW, van Duynhoven YTHP, Simonsen JB, Strid MA, et al.
638 Biomarker dynamics: estimating infection rates from serological data. *Stat Med*. 2012 Sep
639 10;31(20):2240–8.
- 640 29. Schmidt WP, Devamani CS, Rose W, Alexander N, Prakash JAJ. Antibody response following
641 scrub typhus infection: clinical cohort study. *Tropical Medicine & International Health*.
642 2019;24(12):1455–64.
- 643 30. Devamani CS, Prakash JAJ, Alexander N, Stenos J, Schmidt WP. The incidence of *Orientia*
644 *tsutsugamushi* infection in rural South India. *Epidemiol Infect*. 2022 Jun 29;150:e132.
- 645 31. Chanyasanha C, Kaeburong K, Chenchittikul M, Sujirarat D. Seroprevalence of scrub typhus
646 infection in patients with pyrexia at some malaria clinics in three western provinces of Thailand.
647 *Asian Pac J Allergy Immunol*. 1998;16(2–3):119–25.
- 648 32. Devamani CS, Prakash JAJ, Alexander N, Suzuki M, Schmidt WP. Hospitalisations and
649 outpatient visits for undifferentiated fever attributable to scrub typhus in rural South India:
650 Retrospective cohort and nested case-control study. *PLoS Negl Trop Dis*. 2019 Feb
651 25;13(2):e0007160.
- 652